Analysts expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to report $6.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for CymaBay Therapeutics’ earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $10.00 million. The firm is scheduled to announce its next earnings report on Thursday, March 22nd.

According to Zacks, analysts expect that CymaBay Therapeutics will report full-year sales of $6.75 million for the current fiscal year, with estimates ranging from $4.80 million to $14.79 million. For the next financial year, analysts anticipate that the firm will report sales of $0.00 per share. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover CymaBay Therapeutics.

Get CymaBay Therapeutics Inc alerts:

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same quarter last year, the business earned ($0.25) earnings per share.

Several equities research analysts have issued reports on CBAY shares. Cantor Fitzgerald started coverage on CymaBay Therapeutics in a report on Tuesday, September 19th. They set an “overweight” rating and a $16.00 price target for the company. Zacks Investment Research raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 18th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Friday, October 27th. Ifs Securities downgraded CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $14.50.

In other news, SVP Charles Mcwherter acquired 5,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were purchased at an average price of $8.67 per share, for a total transaction of $43,350.00. Following the transaction, the senior vice president now directly owns 10,300 shares of the company’s stock, valued at $89,301. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kurt Von Emster sold 108,876 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The disclosure for this sale can be found here. Insiders have sold a total of 447,257 shares of company stock worth $3,730,862 in the last quarter. Company insiders own 15.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Ardsley Advisory Partners increased its position in CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 20,000 shares during the period. EAM Investors LLC bought a new position in shares of CymaBay Therapeutics in the third quarter worth $4,788,000. Omega Fund Management LLC increased its position in shares of CymaBay Therapeutics by 82.9% in the third quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after purchasing an additional 250,000 shares during the period. Vanguard Group Inc. increased its position in shares of CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after purchasing an additional 170,126 shares during the period. Finally, Marshall Wace North America L.P. bought a new position in shares of CymaBay Therapeutics in the second quarter worth $242,000. Hedge funds and other institutional investors own 68.77% of the company’s stock.

Shares of CymaBay Therapeutics (CBAY) traded up $0.05 during trading on Friday, reaching $8.71. The company’s stock had a trading volume of 573,250 shares, compared to its average volume of 536,157. CymaBay Therapeutics has a fifty-two week low of $1.46 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/02/brokerages-anticipate-cymabay-therapeutics-inc-cbay-will-announce-quarterly-sales-of-6-75-million.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.